Level Four Advisory Services LLC lessened its position in GSK plc (NYSE:GSK – Free Report) by 10.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,102 shares of the pharmaceutical company’s stock after selling 2,022 shares during the period. Level Four Advisory Services LLC’s holdings in GSK were worth $610,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of GSK. Fairfield Bush & CO. bought a new stake in GSK in the first quarter valued at approximately $80,000. JPMorgan Chase & Co. increased its position in shares of GSK by 2.3% during the first quarter. JPMorgan Chase & Co. now owns 241,367 shares of the pharmaceutical company’s stock worth $10,514,000 after acquiring an additional 5,518 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in shares of GSK during the first quarter worth $467,000. Blair William & Co. IL increased its position in shares of GSK by 3.0% during the first quarter. Blair William & Co. IL now owns 37,192 shares of the pharmaceutical company’s stock worth $1,620,000 after acquiring an additional 1,094 shares in the last quarter. Finally, Cetera Investment Advisers increased its position in shares of GSK by 2.4% during the first quarter. Cetera Investment Advisers now owns 62,991 shares of the pharmaceutical company’s stock worth $2,744,000 after acquiring an additional 1,453 shares in the last quarter. Institutional investors own 13.53% of the company’s stock.
GSK Stock Performance
Shares of GSK opened at $37.43 on Monday. The stock has a market capitalization of $76.64 billion, a price-to-earnings ratio of 4.27, a PEG ratio of 1.98 and a beta of 0.68. The company has a current ratio of 0.88, a quick ratio of 0.63 and a debt-to-equity ratio of 1.28. The firm has a fifty day simple moving average of $35.54 and a 200 day simple moving average of $35.48. GSK plc has a 12 month low of $28.47 and a 12 month high of $39.74.
GSK Cuts Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 18th will be paid a $0.3613 dividend. This represents a $1.45 dividend on an annualized basis and a yield of 3.86%. The ex-dividend date is Thursday, August 17th. GSK’s dividend payout ratio is currently 16.10%.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the stock. HSBC assumed coverage on shares of GSK in a research report on Friday, July 14th. They set a “reduce” rating for the company. StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 2nd. Four equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $1,533.00.
Get Our Latest Analysis on GSK
About GSK
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Further Reading
- Five stocks we like better than GSK
- How to Invest in Energy
- 3 Reasons This Sleeping Giant Is About To Wake Up
- How to Buy Metaverse Stock Step by Step
- MarketBeat Week in Review – 9/18 – 9/22
- How to Invest in Mining Stocks
- 52-week Low Names To Tip The Upside Scale In Your Favor
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
